Bucillamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bucillamine
Accession Number
DB12160
Type
Small Molecule
Groups
Investigational
Description

Bucillamine has been used in trials studying the treatment and prevention of Gout and Rheumatoid Arthritis.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
R80LRA5WTF
CAS number
65002-17-7
Weight
Average: 223.31
Monoisotopic: 223.033685631
Chemical Formula
C7H13NO3S2
InChI Key
VUAFHZCUKUDDBC-BYPYZUCNSA-N
InChI
InChI=1S/C7H13NO3S2/c1-7(2,13)6(11)8-4(3-12)5(9)10/h4,12-13H,3H2,1-2H3,(H,8,11)(H,9,10)/t4-/m0/s1
IUPAC Name
(2R)-2-[(1-hydroxy-2-methyl-2-sulfanylpropylidene)amino]-3-sulfanylpropanoic acid
SMILES
[H][[email protected]@](CS)(N=C(O)C(C)(C)S)C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Bucillamine.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Bucillamine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Bucillamine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Bucillamine is combined with 5-androstenedione.Experimental, Illicit
AbciximabBucillamine may increase the anticoagulant activities of Abciximab.Approved
AcebutololBucillamine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Bucillamine.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Bucillamine is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolBucillamine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bucillamine.Approved, Vet Approved
AclarubicinBucillamine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Bucillamine.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Bucillamine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Aldosterone.Experimental, Investigational
AldoxorubicinBucillamine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Bucillamine is combined with Alendronic acid.Approved
AliskirenBucillamine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Bucillamine is combined with Alminoprofen.Experimental
AlprenololBucillamine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Bucillamine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Amcinonide.Approved
AmikacinBucillamine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideBucillamine may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinBucillamine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodBucillamine may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Bucillamine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Bucillamine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Bucillamine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Bucillamine.Investigational
AnnamycinBucillamine may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Bucillamine.Approved, Investigational
Antithrombin III humanBucillamine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanBucillamine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Bucillamine is combined with Apocynin.Investigational
ApramycinBucillamine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Bucillamine.Approved, Investigational
ArbekacinBucillamine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinBucillamine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanBucillamine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololBucillamine may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Atamestane.Investigational
AtenololBucillamine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Bucillamine.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Bucillamine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Bucillamine is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bucillamine.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Bucillamine.Investigational
BalsalazideBucillamine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminBucillamine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololBucillamine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinBucillamine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bucillamine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bucillamine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Bucillamine.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bucillamine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Betamethasone.Approved, Vet Approved
BetaxololBucillamine may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Bucillamine.Approved, Investigational
BevantololBucillamine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bucillamine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Bucillamine.Approved, Investigational
BisoprololBucillamine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinBucillamine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololBucillamine may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Bucillamine.Approved
BucindololBucillamine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bucillamine is combined with Bufexamac.Approved, Experimental
BufuralolBucillamine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Bucillamine.Approved
BupranololBucillamine may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Bucillamine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bucillamine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Bucillamine is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Bucillamine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Bucillamine.Approved, Vet Approved, Withdrawn
CarteololBucillamine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolBucillamine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Bucillamine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Bucillamine is combined with Celecoxib.Approved, Investigational
CeliprololBucillamine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinBucillamine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Bucillamine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bucillamine.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Bucillamine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Bucillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Bucillamine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Cilazapril.Approved
CinoxacinBucillamine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidBucillamine may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Bucillamine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Bucillamine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Bucillamine.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Bucillamine.Vet Approved
CloranololBucillamine may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Bucillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Bucillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Bucillamine.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Bucillamine.Experimental
CyclosporineBucillamine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateBucillamine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinBucillamine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBucillamine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanBucillamine may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinBucillamine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Bucillamine is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Bucillamine is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Delapril.Experimental
DesirudinBucillamine may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bucillamine.Approved, Investigational
DextranBucillamine may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Bucillamine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Bucillamine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Bucillamine may increase the anticoagulant activities of Dextran 75.Approved
DibekacinBucillamine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Bucillamine is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bucillamine.Approved, Vet Approved
DicoumarolBucillamine may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bucillamine.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Bucillamine.Approved
DihydrostreptomycinBucillamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Bucillamine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Bucillamine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Bucillamine.Approved
DoxorubicinBucillamine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneBucillamine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Bucillamine.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Bucillamine.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Bucillamine.Investigational
Edetic AcidBucillamine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBucillamine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Bucillamine is combined with Enalaprilat.Approved
EnoxacinBucillamine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinBucillamine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Bucillamine.Experimental
EpanololBucillamine may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Bucillamine.Approved
EpirubicinBucillamine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Bucillamine.Experimental
EplerenoneBucillamine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Bucillamine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bucillamine.Approved
EquileninThe risk or severity of adverse effects can be increased when Bucillamine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Bucillamine is combined with Equilin.Approved
EsmololBucillamine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bucillamine.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Bucillamine.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Ethenzamide.Experimental
Ethyl biscoumacetateBucillamine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Bucillamine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Bucillamine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Bucillamine.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Bucillamine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Bucillamine.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Bucillamine.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Bucillamine.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Bucillamine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Bucillamine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Bucillamine.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Feprazone.Experimental
Ferulic acidBucillamine may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bucillamine.Approved, Investigational
FleroxacinBucillamine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bucillamine.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fludrocortisone.Approved, Investigational
FluindioneBucillamine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineBucillamine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Bucillamine.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Bucillamine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Bucillamine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bucillamine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bucillamine.Approved, Nutraceutical, Vet Approved
FondaparinuxBucillamine may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumBucillamine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Bucillamine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fosinopril.Approved
FramycetinBucillamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Bucillamine.Approved, Vet Approved
GabexateBucillamine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinBucillamine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinBucillamine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Bucillamine.Approved, Withdrawn
GemifloxacinBucillamine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinBucillamine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinBucillamine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ABucillamine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Bucillamine may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinBucillamine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Bucillamine is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Bucillamine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Bucillamine is combined with HE3286.Investigational
HeparinBucillamine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Higenamine.Investigational
HydralazineBucillamine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bucillamine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bucillamine.Approved, Investigational
Hygromycin BBucillamine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Bucillamine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Bucillamine.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Bucillamine.Approved, Investigational
IdarubicinBucillamine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxBucillamine may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bucillamine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bucillamine.Approved
IndenololBucillamine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Bucillamine is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bucillamine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Bucillamine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bucillamine.Approved, Investigational
IsepamicinBucillamine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Bucillamine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Bucillamine is combined with Istaroxime.Investigational
KanamycinBucillamine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Bucillamine.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Bucillamine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Bucillamine.Approved
LabetalolBucillamine may decrease the antihypertensive activities of Labetalol.Approved
LandiololBucillamine may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Bucillamine.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Bucillamine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Bucillamine.Approved, Investigational
LepirudinBucillamine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanBucillamine may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololBucillamine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinBucillamine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Bucillamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Bucillamine.Approved
LonazolacThe risk or severity of adverse effects can be increased when Bucillamine is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Bucillamine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Bucillamine.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Bucillamine is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Bucillamine.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Bucillamine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Bucillamine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Bucillamine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Bucillamine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bucillamine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Bucillamine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bucillamine.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Bucillamine.Approved
MelagatranBucillamine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Bucillamine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Bucillamine.Approved, Vet Approved
MepindololBucillamine may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineBucillamine may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Bucillamine.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bucillamine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bucillamine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Methylprednisolone.Approved, Vet Approved
MetipranololBucillamine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bucillamine.Approved
MetoprololBucillamine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideBucillamine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinBucillamine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Bucillamine.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bucillamine.Approved
MizoribineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bucillamine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bucillamine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bucillamine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Nabumetone.Approved
NadololBucillamine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinBucillamine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatBucillamine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Bucillamine.Approved
Nalidixic AcidBucillamine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Bucillamine.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Bucillamine is combined with NCX 1022.Investigational
NeamineBucillamine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololBucillamine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinBucillamine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinBucillamine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Bucillamine.Approved, Investigational
NetilmicinBucillamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Bucillamine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bucillamine.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Bucillamine is combined with Nitroaspirin.Investigational
NorfloxacinBucillamine may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bucillamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bucillamine.Approved
OlsalazineBucillamine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Bucillamine is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Bucillamine is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Bucillamine.Vet Approved
OtamixabanBucillamine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Bucillamine.Approved
Oxolinic acidBucillamine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololBucillamine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bucillamine.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Bucillamine is combined with Parecoxib.Approved
ParomomycinBucillamine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Parthenolide.Approved, Investigational
PazufloxacinBucillamine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinBucillamine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololBucillamine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateBucillamine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateBucillamine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Perindopril.Approved
PhenindioneBucillamine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonBucillamine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bucillamine.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bucillamine.Approved, Investigational
PindololBucillamine may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidBucillamine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinBucillamine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Bucillamine.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Bucillamine.Approved, Investigational
Piromidic acidBucillamine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bucillamine.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorBucillamine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinBucillamine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinBucillamine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bucillamine.Approved
PractololBucillamine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Bucillamine.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Bucillamine can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Bucillamine is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Bucillamine.Approved, Investigational
PropranololBucillamine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Bucillamine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Bucillamine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Bucillamine.Vet Approved
Protein CBucillamine may increase the anticoagulant activities of Protein C.Approved
Protein S humanBucillamine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBucillamine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinBucillamine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Bucillamine.Investigational
PuromycinBucillamine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bucillamine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Bucillamine.Approved, Experimental, Investigational
ReviparinBucillamine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinBucillamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Risedronate.Approved, Investigational
RivaroxabanBucillamine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Bucillamine is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinBucillamine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinBucillamine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinBucillamine may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Bucillamine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Bucillamine.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bucillamine.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Bucillamine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bucillamine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Bucillamine.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Bucillamine.Approved, Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Bucillamine.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Bucillamine.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Bucillamine is combined with Serrapeptase.Investigational
SisomicinBucillamine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinBucillamine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Bucillamine.Approved
SotalolBucillamine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CBucillamine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinBucillamine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinBucillamine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Spirapril.Approved
SpironolactoneBucillamine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Bucillamine.Investigational
StreptomycinBucillamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinBucillamine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bucillamine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Bucillamine.Approved, Investigational
SulodexideBucillamine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Bucillamine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Bucillamine.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Suxibuzone.Experimental
TacrolimusBucillamine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Bucillamine.Approved
TalinololBucillamine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Bucillamine.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Bucillamine.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Bucillamine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Bucillamine is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bucillamine.Approved, Investigational
TemafloxacinBucillamine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Bucillamine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Bucillamine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Bucillamine.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Bucillamine.Approved
TertatololBucillamine may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Bucillamine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Bucillamine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololBucillamine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Bucillamine is combined with Tixocortol.Approved, Withdrawn
TobramycinBucillamine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bucillamine.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bucillamine.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Bucillamine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Bucillamine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bucillamine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bucillamine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Bucillamine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneBucillamine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Bucillamine is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Bucillamine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Bucillamine.Investigational
TrovafloxacinBucillamine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinBucillamine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Bucillamine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Bucillamine.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Bucillamine is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinBucillamine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bucillamine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Bucillamine.Approved
WarfarinBucillamine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBucillamine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bucillamine.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Bucillamine.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Bucillamine is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Bucillamine is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bucillamine.Withdrawn
Zoptarelin doxorubicinBucillamine may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinBucillamine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
656604
PubChem Substance
347828452
ChemSpider
570965
BindingDB
50406934
ChEBI
31312
ChEMBL
CHEMBL80830
PharmGKB
PA166123566
Wikipedia
Bucillamine
ATC Codes
M01CC02 — Bucillamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAcute Gouty Arthritis1
2RecruitingTreatmentCystine renal calculi1
3CompletedTreatmentRheumatoid Arthritis1
4Unknown StatusPreventionRheumatoid Arthritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.401 mg/mLALOGPS
logP1.08ALOGPS
logP1.34ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)3.94ChemAxon
pKa (Strongest Basic)0.68ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area69.89 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity55.23 m3·mol-1ChemAxon
Polarizability21.94 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-acyl-l-alpha-amino acids. These are n-acylated alpha amino acids which have the L-configuration of the alpha-carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
N-acyl-L-alpha-amino acids
Alternative Parents
Cysteine and derivatives / Secondary carboxylic acid amides / Monocarboxylic acids and derivatives / Carboxylic acids / Alkylthiols / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
N-acyl-l-alpha-amino acid / Cysteine or derivatives / Carboxamide group / Secondary carboxylic acid amide / Alkylthiol / Carboxylic acid / Monocarboxylic acid or derivatives / Organic oxygen compound / Organosulfur compound / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:30 / Updated on March 02, 2018 04:07